此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

肾脏疾病试验的议程制定 (ASK)

2026年11月11日 更新者:Catherine Hylas Saunders、Dartmouth-Hitchcock Medical Center

设定议程:一名飞行员梯级楔形集群随机试验,该试验是针对患有晚期慢性肾脏病的农村人士的结构化临床访问议程制定干预措施

The goal of this clinical trial is to learn if a tool with a list of discussion topics, called a structured clinical visit agenda-setting intervention (SAS), works for people with advanced chronic kidney disease (CKD) who receive care at a clinic that serves people who live in rural areas. The SAS is called CKD Topics. The researchers will compare the SAS intervention to usual care (the way clinicians usually practice) to see how well it works for people with advanced CKD. This is a special type of clinical trial called a stepped wedge randomized clinical trial (RCT). In this type of trial, every participant will get to experience both usual care and CKD Topics, but for different amounts of time.

The researchers will learn if doing a clinical trial of CKD Topics is possible (feasible) and get information about how well CKD Topics helps people with advanced CKD shape visit discussions (self-advocacy) in their appointments with their clinicians. The information the researchers collect in this trial will help design a future trial with more participants.

The main questions the researchers aim to answer are:

  • Is it possible to conduct this type of study of a SAS intervention? i.e. feasibility
  • Does the SAS intervention help people with advanced CKD shape discussions (self-advocacy) with their clinicians? If so, how much? i.e. preliminary efficacy

研究概览

详细说明

This stepped-wedge pilot randomized controlled trial (RCT) is to test a new structured agenda-setting (SAS), called the Chronic Kidney Disease (CKD) Topics Agenda-Setting Tool, with patients, their care partners and their clinicians. This is a pilot study, so the researchers are collecting feasibility data to determine if a larger, fully-powered RCT can be moved forward. The researchers are also collecting preliminary efficacy data, which will help the design of a future study on the efficacy of clinical visits for people with advanced CKD.

This study has two arms: 1) a usual care arm, and 2) an intervention arm where participants and their nephrology physicians will use CKD Topics during their visits. Physicians will initially be randomly assigned to one of three clusters, with two attending physicians and one fellow physician in each cluster. Each cluster will start out practicing usual care for at least eight months during the enrollment period. After that initial 8 months, one cluster will cross over to the intervention arm every four months, by using the CKD Topics tool in their visits, in what's called the rollout period. At 16 months into the trial, all clusters will be on the intervention arm, using CKD topics with patients, and will do so for the remaining 12 months of the trial.

Patient participants will be enrolled in the study arm to which their physicians have been randomized. Participation is expected to last 24 months for patients and clinicians, and participants may use CKD Topics more than once during the study period. The researchers expect 108 patient participants, and nine clinicians will enroll in the study. Every participant will receive a baseline survey after enrollment and four subsequent surveys.

The procedures in this study will include screening patients for study eligibility, consenting them to participate in study activities such as filling out surveys. The intervention, CKD topics, itself will be administered as quality improvement so will not be included as a research activity needing consent.

Future Directions: Findings from this trial will forecast a range of participants required in the sample for a full-scale RCT and illustrate "proof of concept" for a future trial which will evaluate the intervention's impact on patient self-advocacy and clinical care outcomes in rural CKD populations.

研究类型

介入性

注册 (估计的)

108

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • New Hampshire
      • Lebanon、New Hampshire、美国、03766
        • Dartmouth Hitchcock Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults >18 years old who have been diagnosed with advanced CKD (stages 4-5).
  • Care partners, clinicians and staff supporting these CKD patients who are willing and able to provide informed consent
  • English-speaking
  • Able to provide informed consent
  • Patient must be attending outpatient visits *(in-person and/or telehealth allowable).

Exclusion Criteria:

  • Children under 18 years old will not be included
  • Non-English-speaking patients and/or care partners
  • Patients on dialysis
  • Individuals unable or unwilling to provide informed consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Arm 1 is Usual Care

The clinicians in the nephrology clinic will proceed with usual care without intervention from the study team.

实验性的:Arm 2 is Clinical Visit Agenda Setting Tool Intervention

The study team will implement a structured clinical visit agenda-setting (SAS) intervention customized for advanced chronic kidney disease, called Chronic Kidney Disease (CKD) Topics.

Chronic Kidney Disease (CKD) Topics is a novel clinical visit agenda-setting intervention developed through participatory research methods for people with CKD living in rural areas. CKD Topics includes structured discussion topic areas.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Feasibility Outcome
大体时间:From enrollment to the end of treatment at 16 months

The primary outcome will be feasibility, assessed by the proportion of patients who received the intervention.

From enrollment to the end of treatment at 16 months

次要结果测量

结果测量
措施说明
大体时间
Secondary Feasibility Outcome
大体时间:From enrollment to the end of treatment at 16 months

The secondary outcome will be feasibility assessed by the clinicians' intention to continue the intervention use, measured in a survey.

From enrollment to the end of treatment at 16 months

其他结果措施

结果测量
措施说明
大体时间
Primary Process Outcome: Enrollment Rate
大体时间:From enrollment to the end of treatment at 16 months

As measured by participant enrollment in Redcap.

From enrollment to the end of treatment at 16 months
Secondary Process Outcome: Loss to follow-up
大体时间:From enrollment to the end of treatment at 16 months

As measured by participant dropout (loss to follow-up) in Redcap.

From enrollment to the end of treatment at 16 months
Preliminary Efficacy Outcome: Patient Self-Advocacy Scale (PSAS)
大体时间:From enrollment to the end of treatment at 16 months

The Patient Self-Advocacy Scale (PSAS); a 12-item validated scale assessing the latent construct of perceived self-advocacy for patients.

From enrollment to the end of treatment at 16 months
Preliminary Efficacy Outcome: Patient self-efficacy
大体时间:From enrollment to the end of treatment at 16 months

Patient self-efficacy measured using the Ask, Understand, Remember Assessment, (AURA); a validated 4-item assessment of self-efficacy completed by patients.

From enrollment to the end of treatment at 16 months
Preliminary Efficacy Outcome: Patient self-management
大体时间:From enrollment to the end of treatment at 16 months

Patient demonstration of self-management using the Perceived Medical Condition Self-Management Scale; an 8-item instrument validated to assess self-management among CKD patients; correlated with treatment adherence.

From enrollment to the end of treatment at 16 months
Preliminary Efficacy Outcome: Unplanned hospitalization or emergency department visit
大体时间:From enrollment to the end of treatment at 16 months

Unplanned hospitalization or emergency department visit. EHR chart review and patient self-report.

From enrollment to the end of treatment at 16 months
Preliminary Efficacy Outcome: Serious Illness Experience
大体时间:From enrollment to the end of treatment at 16 months

Serious illness experience measured by the consideRATE questions; a validated 8-item, plain language (2nd grade) patient-reported experience measure (PREM) with Likert-like response options for patients, and care partners.

From enrollment to the end of treatment at 16 months
Preliminary Efficacy Outcome: Respect Experience Assessment
大体时间:From enrollment to the end of treatment at 16 months

Respect experience assessment measured by the "Heard and Understood" tool. Heard and Understood is a validated Single-item PREM with Likert-like response options for patients.

From enrollment to the end of treatment at 16 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年3月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2025年6月9日

首先提交符合 QC 标准的

2025年6月9日

首次发布 (实际的)

2025年6月17日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

The study will use standard processing and documentation protocols adopted by the Inter-university Consortium for Political and Social Research (ICPSR) for data formats, dictionaries, variable names, descriptions, and labels. An XML schema using Data Documenting Initiative standards will also be used for codebooks and other metadata as appropriate. The researchers will share RCT process and outcomes data in CSV files via openICPSR, which is a self-publishing repository for social, behavioral and health science data and part of the ICPSR.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅